Research is key to future treatment
The BRC is a partnership between The Royal Marsden and The Institute of Cancer Research, London. It supports innovative translational research, taking leading-edge cancer research from the laboratory and rapidly translating it into a clinical setting.
Advance: our magazine
Find out more about the world-leading research carried out through the NIHR Biomedical Research Centre at The Royal Marsden and the ICR - the only BRC in the UK dedicated solely to cancer.
Latest news
News: Men over 40 with BRCA2 gene fault ‘should get regular PSA screening’
Experts are urging that guidelines should change so that all men over the age of 40 with faults in the BRCA2 gene should be offered regular PSA testing to detect early signs of prostate cancer.
Find out more
News: Drug blocking blood vessel growth could treat rare sarcomas
An experimental targeted drug could treat a rare type of cancer usually affecting the limbs, a clinical trial led by The Institute of Cancer Research, London, has shown.
Find out more
News: 'evolution-busting' drug overcomes resistance in aggressive breast
A new type of drug that blocks one of cancer’s key evolutionary escape routes from chemotherapy could be used to treat aggressive breast cancers.
Find out more